1. Luxembourg Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
Eurofins Scientific SE

Eurofins Scientific SE

83.00
EUR
+2.40
(+2.98%)
11.00BMarket Cap
Mar 02Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
8.17
9.32
12.75
15.86
17.38
21.36
25.63
29.21
35.08
34.87
33.77
36.47
40.58
- -
Basic EPS, GAAP
0.48
0.52
0.57
1.09
1.27
1.26
1.1
2.9
4.09
3.17
1.61
2.13
2.64
- -
Free Cash Flow per Basic Share
0.47
0.51
0.8
1.08
0.93
1.01
2
4.66
5.25
2.47
2.43
4.15
3.14
- -
Dividend per Share
0.1
0.12
0.13
0.14
0.2
0.24
0.29
- -
0.68
1
0.99
0.5
0.6
- -
Book Value per Share
2.57
4.32
6.22
9.62
13.85
15.04
15.85
19.34
24.17
24.84
26.44
28.58
25.71
25.71
Tangible Book Value per Share
-1.03
-1.42
-5.24
-2.01
-4.52
-9.55
-9.43
-3.45
-1.89
-3.43
-1.41
-1.55
-4.55
-4.55
Basic Weighted Avg Shares
150
151
153
160
171
177
178
186
192
193
193
191
180
180
Sales/Revenue/Turnover
1,226
1,410
1,950
2,537
2,971
3,781
4,563
5,439
6,718
6,712
6,515
6,951
7,296
- -
Operating Margin (%)
9.1
9.45
10.51
11.03
9.67
8.9
7.04
14.81
18.98
11.67
8.39
10.45
11.22
- -
Depreciation Expense
67
81
111
142
176
224
396
426
451
504
565
597
630
- -
Net Income, GAAP
72
79
87
174
217
224
195
539
783
610
310
406
475
- -
Effective Tax Rate (%)
19.28
21.91
31.91
26.83
12.5
22.88
28.1
22.16
25.89
22.33
27.29
26.88
27.69
- -
Profit Margin (%)
5.89
5.61
4.48
6.86
7.3
5.92
4.28
9.92
11.65
9.09
4.76
5.85
6.51
- -
Working Capital
306
170
649
869
375
255
23
822
463
541
945
342
224
224
LT Debt
667
638
1,497
1,340
1,662
2,766
3,087
2,917
2,500
3,112
3,326
3,132
3,705
3,705
Total Equity
395
664
1,080
1,757
2,482
2,722
2,898
3,716
4,677
4,851
5,137
5,385
4,577
4,577
Return on Invested Capital (%)
6.76
5.82
4.02
6.52
6.24
4.73
4.04
8.77
12.12
8.54
4.23
5.22
5.94
- -
Return on Capital (%)
9.65
8.46
5.81
7.45
6.71
5.2
4.31
9.3
11.92
8.93
4.72
5.73
6.56
- -
Return on Common Equity (%)
19.04
15.15
10.82
13.46
10.65
8.76
7.09
16.52
18.77
12.94
6.29
7.8
9.61
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
479
538
727
LT Borrowings
2,674
3,172
3,407
LT Finance Leases
457
403
298
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
187
178
177
Market Capitalization
9,158
10,855
10,998

Working Capital

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
2,452
2,619
2,654
Cash, Cash Equivalents & STI
614
753
791
Accounts Receivable, Net
1,094
1,070
1,097
Inventories
142
146
139
Total Current Liabilities
2,110
2,085
2,430
Payables & Accruals
- -
- -
- -
ST Debt
479
538
727
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.35%
5.06%
-15.01%
Free Cash Flow
29.03%
0.35%
-28.64%
Net Income, GAAP
31.24%
4.35%
16.83%
Sales/Revenue/Turnover
14.65%
6.43%
4.96%
Total Cash Common Dividend
2,599.88%
5,197.94%
12.66%

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
6,515
2024
- -
- -
6,951
2025
- -
- -
7,296

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1.61
2024
- -
- -
2.13
2025
- -
- -
2.64

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.99
2024
- -
- -
0.5
2025
- -
- -
0.6

Company Description

Company Profile APIChatGPT
CEO
Gilles G. Martin
Full Time Employees
65,694
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
23 Val Fleuri Luxembourg LU Luxembourg 1526
IPO Date
Oct 24, 1997
Website
eurofins.com
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
Eurofins Scientific SE is a global leader in bioanalytical testing services, offering a comprehensive portfolio of laboratory services across multiple industries including food, pharmaceuticals, environmental, consumer products, clinical diagnostics, and agroscience. The company manufactures and provides analytical testing, inspection, and certification services including food safety testing, pharmaceutical bioanalytical and clinical testing, environmental air, water and soil analysis, consumer product testing for cosmetics and technology products, genomics and molecular diagnostic testing, biopharma contract development and manufacturing, and advanced material sciences. Eurofins operates over 950 laboratories in more than 60 countries and serves a broad customer base consisting of regulatory bodies, multinational corporations, clinical research organisations, and agricultural producers. Founded in 1987 and headquartered in Luxembourg, Eurofins has grown through significant acquisitions and organic expansion to become a dominant player in global testing services. In the last 1-2 years, Eurofins has made several strategic advancements, including completing over 30 acquisitions with pro forma revenues of approximately €225 million and continuing to invest heavily in research and development, allocating around €200 million annually. The company launched innovative assays such as the SH2scan™ for drug discovery using advanced KINOMEscan® technology and expanded its clinical diagnostics and in-vitro diagnostic product offerings. Eurofins has focused on improving operational efficiency through full digitalization and developing a hub and spoke laboratory network to enhance service quality and client responsiveness. The company also pursues sustainability initiatives, aiming to reduce its carbon footprint by 30% by 2030, and has committed to significant growth in emerging markets. As of 2024-2025, Eurofins reported revenues exceeding €7 billion with EBITDA margins improving to over 22%, reinforcing its financial strength and competitive positioning in the bioanalytical testing sector. Eurofins’ industry segments encompass Food Testing, Pharmaceutical Testing, Environmental Testing, Consumer Products Testing, Genomics, Clinical Diagnostics, and Biopharma Contract Development and Manufacturing. Its clients span regulatory agencies, multinational corporations in pharmaceuticals, food and agriculture, environmental regulators, and consumer product manufacturers. The company operates through a decentralized model leveraging local expertise while maintaining consistent global quality standards. This global footprint is supported by over 65,000 employees worldwide and a portfolio of more than 200,000 analytical methods to ensure safety, identity, composition, authenticity, and traceability of products tested. Eurofins is publicly traded on Euronext Paris under the ticker ERF.PA and has a market capitalization around €11 billion as of late 2025. Eurofins Scientific SE’s recent major operational changes include the acquisition of SYNLAB’s clinical diagnostics operation in Spain, contributing to geographic expansion and service diversification, and launching 18 new startup laboratories and 32 blood collection points in 2024 alone to drive organic growth. The company also implemented pricing adjustments to better align with inflation amidst the evolving macroeconomic landscape and sustained growth in BioPharma despite cyclical softness in certain end markets. These initiatives support Eurofins’ mid-term financial targets, including strong organic revenue growth, margin expansion, improved cash conversion, and market share gains particularly in genomics and environmental testing sectors. Overall, Eurofins Scientific SE continues to leverage acquisitions, innovation, and strategic expansion to solidify its position as a global leader in laboratory testing services serving multiple critical industries worldwide. The company maintains a strong focus on operational efficiency, service excellence, sustainable practices, and advanced scientific methodologies as key pillars of its ongoing growth and market leadership strategy.

Company News

Company News APIChatGPT